Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win

After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data in tandem with the multiple myeloma field’s hottest drug could help boost it even further.

Adding Johnson & Johnson’s Darzalex to a combination of Kyprolis and the steroid dexamethasone cut patients’ risk of disease progression or death by 37% compared with Kyprolis and dexamethasone alone, the Big Biotech said.